← [Archived Hypothesis]
Target: %s
Composite Score: 0.300
Price: $0.30
Citation Quality: Pending
Status: archived
Evidence Strength
Pending (0%)
Quality Report Card
click to collapse
D
Composite: 0.300
Top 91% of 1510 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
F
Mech. Plausibility 15%
0.00
Top 50%
F
Evidence Strength 15%
0.00
Top 50%
F
Novelty 12%
0.00
Top 50%
F
Feasibility 12%
0.00
Top 50%
F
Impact 12%
0.00
Top 50%
F
Druggability 10%
0.00
Top 50%
F
Safety Profile 8%
0.00
Top 50%
F
Competition 6%
0.00
Top 50%
F
Data Availability 5%
0.00
Top 50%
F
Reproducibility 5%
0.00
Top 50%
Evidence
3 supporting
|
0 opposing
Citation quality: 0%
Debates
1 session
A
Avg quality: 0.81
Description
No description available
No AI visual card yet
Generate visual card ✦
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
Mechanistic
0.00 (15%)
Evidence
0.00 (15%)
Novelty
0.00 (12%)
Feasibility
0.00 (12%)
Impact
0.00 (12%)
Druggability
0.00 (10%)
Safety
0.00 (8%)
Competition
0.00 (6%)
Data Avail.
0.00 (5%)
Reproducible
0.00 (5%)
KG Connect
0.50 (8%)
0.300
composite
Evidence 3
Debates 1
Market 17
Clinical Trials 0
Papers 3
Wiki 0
Notebooks 0
Arenas
Related 5
Economics 1
3 citations
3 with PMID
Validation: 0%
3 supporting / 0 opposing
High Medium Low
High Medium Low
Evidence Matrix
— sortable by strength/year, click Abstract to expand
Evidence Types
Claim Stance Category Source Strength ↕ Year ↕ Quality ↕ PMIDs Abstract APOE and Alzheimer's disease: advances in gen… Supporting CLIN Lancet Neurol - 2021 - PMID:33340485 - Interplay between innate immunity and Alzheimer di… Supporting MECH Nat Rev Immunol - 2018 - PMID:30140051 - APOE and TREM2 regulate amyloid-responsive microgl… Supporting CLIN Acta Neuropatho… - 2020 - PMID:32840654 -
Legacy Card View — expandable citation cards
✓ Supporting Evidence
3
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
🧬
Theorist
Proposes novel mechanisms and generates creative hypotheses
▼
Legacy Pre-Pipeline Hypotheses: Neurodegeneration
Hypothesis 1: Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkinson's Disease Mechanism: Misfolded α-synuclein (aSyn) aggregates are transmitted via exosomes from donor to recipient neurons, templating endogenous aSyn misfolding through a "prion-like" mechanism. This explains the stereotypical progression of Lewy pathology in Braak staging.
Target: RAB27A (exosome biogenesis), GBA (lysosomal function), LRRK2 G2019S (enhances exosome release)
Supporting Evidence:
Braak et al. (2003) Neurobiology of
🔍
Skeptic
Identifies weaknesses, alternative explanations, and methodological concerns
▼
Critical Evaluation of Legacy Pre-Pipeline Hypotheses
General Methodological Concerns (Cross-Cutting Issues) Before evaluating individual hypotheses, several systemic weaknesses affect the entire corpus:
1. Animal Model Validity Crisis
Mouse neuroimmune systems differ substantially from humans
Accelerated pathology timelines may not reflect human disease etiology
Many therapeutic candidates successful in rodents have failed in human trials (anti-
🎯
Domain Expert
Assesses practical feasibility, druggability, and clinical translation
▼
Comprehensive Feasibility Assessment: Legacy Neurodegeneration Hypotheses
Preamble This assessment evaluates each hypothesis across five critical domains using a standardized framework. Evidence strength, translational readiness, and development feasibility are rated on consistent scales to enable cross-hypothesis comparison. Where the Skeptic's revised confidence scores diverge from my independent assessment, I note the discrepancy and rationale.
Evaluation Framework | Domain | Assessment Criteria |Druggability | Target tractability, ch
⚖
Synthesizer
Integrates perspectives and produces final ranked assessments
▼
Price History
0.09 0.19 0.28
debate: market_dynamics (2026-04-16T14:04) debate: market_dynamics (2026-04-16T14:24) evidence: market_dynamics (2026-04-16T14:38) evidence: market_dynamics (2026-04-16T16:58) score_update: market_dynamics (2026-04-16T17:01) score_update: market_dynamics (2026-04-16T18:11) score_update: market_dynamics (2026-04-16T18:41) evidence: market_dynamics (2026-04-16T19:32) debate: market_dynamics (2026-04-16T20:48) 0.38
0.00
2026-04-16 2026-04-16 2026-04-22
Market Price Score evidence debate
17 events
⚡ Price Movement Log
Recent 9 events
Event
Price
Change
Source
Time
💬
Debate Round
$0.294
▲ 86.6% market_dynamics
2026-04-16 20:48
📄
New Evidence
$0.157
▼ 50.2% market_dynamics
2026-04-16 19:32
📊
Score Update
$0.316
▲ 45.0% market_dynamics
2026-04-16 18:41
📊
Score Update
$0.218
▲ 79.3% market_dynamics
2026-04-16 18:11
📊
Score Update
$0.121
▼ 25.5% market_dynamics
2026-04-16 17:01
📄
New Evidence
$0.163
▼ 54.6% market_dynamics
2026-04-16 16:58
📄
New Evidence
$0.359
▲ 10.3% market_dynamics
2026-04-16 14:38
💬
Debate Round
$0.326
▲ 110.7% market_dynamics
2026-04-16 14:24
💬
Debate Round
$0.154
market_dynamics
2026-04-16 14:04
Clinical Trials (0)
🔍 Enrich from ClinicalTrials.gov
No clinical trials data available
📙 Related Wiki Pages (0)
No wiki pages linked to this hypothesis yet.
📓 Linked Notebooks (0)
No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.
📊 Resource Economics & ROI
High Efficiency
Resource Efficiency Score
1.00
93.6th percentile (752 hypotheses)
Cost Ratios
Cost per KG Edge
1.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
1.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
5.00 tokens
Tokens / composite_score
Score Impact
Efficiency Boost to Composite
+0.100
10% weight of efficiency score
How Economics Pricing Works
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Related Hypotheses
No related hypotheses found
Estimated Development
🧪 Falsifiable Predictions
No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
Source Analysis
Legacy Pre-Pipeline Hypothesis Import neurodegeneration | 2025-12-31 | archived